Ileana Piña, MD, gets the details on the FINEARTS-HF trial of finerenone in patients with heart failure with preserved ejection fraction from the principal investigator Scott Solomon, MD.
Professor of Medicine, Cardiology, Heart Failure , and Transplant; Quality Officer, Cardiovascular Line, Sidney Kimmel College of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania; Clinical Professor of Medicine, Central Michigan University College of Medicine, Mount Pleasant, Michigan; Adjunct Professor of Epidemiology and Biostatistics, Population & Quantitative Health Sciences, Case Western University, Cleveland, OhioServe as a director, office, partner, employee, advisor,...
Received research grant from: Alexion; Alnylam; Applied Therapeutics; AstraZeneca; Bellerophon; Bayer; BMS; Boston Scientific; Cytokinetics; Edgewise; Eidos/BridgeBio; Gossamer; GSK; Ionis; Lilly; NIH/NHLBI; Novartis; Novo Nordisk; Respicardia; Sanofi Pasteur; Tenaya; Theracos;Hello. I'm Ileana Piña, and I am here at the European Society of Cardiology Congress in beautiful London. I have with me my good friend Scott Solomon from the Brigham at Harvard. Scott, welcome.
In HFpEF trials, we've never been able to get mortality. Why? Because the event rates in these patients were low, we would have to do trials twice as long or twice as big.You'd have to run trials for 10 years, So would you now tell the clinician audience that they should switch from spironolactone to finerenone?First of all, there's no indication as of yet for finerenone in this population. It's going to go to the FDA, and they'll eventually get approval.
Ileana L. Piña, MD, MPH, is a heart failure and cardiac transplantation expert. She serves as an advisor/consultant to the FDA's Center for Devices and Radiological Health and has been a volunteer for the American Heart Association since 1982. Originally from Havana, Cuba, she is passionate about enrolling more women and minorities in clinical trials. She also enjoys cooking and taking spin classes.
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.Fast Five Quiz: Heart Failure Comorbidities
Antihypertensive Cardiovascular Imaging Cardiac Imaging CV Imaging Heart Cardiomyopathy Transplantation Of The Heart Cardiac Transplantation Heart Transplantation Receptors Ejection Fraction EF - Ejection Fraction Left Ventricular Ejection Fraction LVEF Massachusetts Clinical Guidelines Guidelines Patient Safety Fellowship Fellows Hospitals Residency Residents
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Finerenone Benefits Heart Failure With Preserved EFThe long-debated question of whether mineralocorticoid receptor antagonists are effective for heart failure with mildly reduced or preserved ejection fraction has been answered in a new trial.
Read more »
GLP-1 Receptor Agonists May Lower Mortality in Immune-Mediated Inflammatory Diseases and T2DGLP-1 RAs were associated with a decreased risk for all-cause mortality and MACE in patients with immune-mediated inflammatory diseases and type 2 diabetes.
Read more »
Scientists discover novel receptor recognition mechanism for alphavirusEastern Equine Encephalitis virus (EEEV), an alphavirus, can cause central nervous system infections that can lead to severe encephalitis with a mortality rate of over 30%.
Read more »
– Receptor Pharmacology of Opioid Peptides - Vienna (AT) job with Medical University of ViennaCurrent opioid-based analgesics are effective painkillers but with the drawback of severe side-effect of addiction and respiratory depression, which is the cause for the so-called ‚opioid epidemic‘.
Read more »
Scientists discover stable intermediate of serotonin receptorA new study published in The EMBO Journal points to new potential strategies to treat psychiatric and gastrointestinal disorders that are not well addressed by current medications. Dr.
Read more »
Androgen Receptor Pathway Inhibitors Show Improved Outcomes in Prostate CancerResearchers compared outcomes for patients randomized to receive androgen receptor pathway inhibitors, taxanes, or a physician's choice.
Read more »